Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
Emergent BioSolutions announced a $34.5 million strategic partnership with Substipharm Biologics to manufacture the drug substance of the Japanese Encephalitis vaccine IMOJEV® at Emergent's Canton, Massachusetts facility and to serve as its exclusive distributor to the U.S. government upon FDA approval. This initiative supports onshoring of critica…